Reno, Nevada (UroToday.com) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 17 Decipher-focused abstracts will be presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU). The findings demonstrate the market leadership of its Decipher tests in better informing treatment decisions for patients with prostate and bladder cancers, compared to standard approaches, and in helping to drive innovation that will inform the future of urologic cancer care. The conference will take place February 13-15 in San Francisco.
“The scale and scope of data to be presented at the ASCO GU meeting underscore the impact our whole-transcriptome-based Decipher tests are having in treating patients with urologic cancers, and how our GRID, or Genomic Resource for Intelligent Discovery, research tool is helping to advance scientific understanding of these diseases,” said Elai Davicioni, Ph.D., Veracyte’s medical director, Urology. “Our commitment to generating robust clinical evidence with collaborators has led to our market-leading Decipher Prostate test achieving the highest status among gene expression tests in the most recent, and prior, NCCN guidelines.* We look forward to using a similar approach for our Decipher Bladder test in bladder cancer.”
“Clinical rigor and robust evidence generation are important for a molecular test to gain widespread adoption and inclusion in guidelines for helping physicians and their patients with prostate cancer make better-informed treatment decisions,” said Daniel Spratt, M.D., of the University Hospitals Seidman Cancer Center, Case Western Reserve University. “National guidelines have acknowledged the large body of work from randomized Phase 3 trials that have been profiled with Decipher and include the Decipher test as an advanced risk-stratification tool that can aid in shared-decision making for patients.”
Key Decipher-focused findings to be presented at the ASCO GU Symposium are:
|
Title: |
Decipher Score as a Predictor of Response to Treatment Intensification in the NRG Oncology-RTOG 0534 (SPPORT) Phase III Randomized Post-Prostatectomy Salvage Radiotherapy Trial |
|
|
Presenter: |
Alan Pollack, M.D., Ph.D., University of Miami Health System |
|
|
Format: |
Poster (#K29) |
|
|
Abstract #: |
399 |
|
|
Date/Time: |
Thursday, February 13, 2025; 11:25 a.m.—12:45 p.m. PST |
|
|
Location: |
Level 1, West Hall; On Demand |
|
|
Summary: |
A post-hoc analysis of the NRG Oncology/RTOG 05-34 (SSPORT) Phase 3, randomized trial shows that the Decipher Prostate test may inform treatment intensification strategies in patients undergoing salvage radiotherapy by identifying those who will benefit from pelvic nodal radiation. |
|
Title: |
A non-coding RNA based classifier for favorable outcomes in clinically organ confined bladder cancer |
|
|
Presenter: |
Yair Lotan, M.D., UT Southwestern Medical Center |
|
|
Format: |
Poster (#G27) |
|
|
Abstract #: |
831 |
|
|
Date/Time: |
Friday, February 14, 2025; 11:30 a.m.—12:45 p.m. PST |
|
|
Location: |
Level 1, West Hall; On Demand |
|
|
Summary: |
Study findings show that the Decipher Bladder test accurately identifies patients whose bladder cancer has a luminal molecular subtype, which is associated with favorable outcomes. Such findings could help clinicians determine which patients are less likely to benefit from intensified therapy. |
|
Title: |
Gene signature predictor of dose-response to prostate radiation: validation of PORTOS in phase III trials |
|
|
Presenter: |
Shuang Zhao, M.D., University of Wisconsin-Madison |
|
|
Format: |
Oral Presentation |
|
|
Abstract #: |
308 |
|
|
Date/Time: |
Thursday, February 13, 2025; 8:00 a.m.—9:40 a.m. PST |
|
|
Location: |
Level 3, Ballroom; Live Stream |
|
|
Summary: |
Analyses of two prospective, randomized, Phase 3 trials (RTOG 01-26 and SAKK 09/10) show that the PORTOS gene expression signature – currently part of the Decipher GRID research tool – predicts which patients will benefit from dose-escalated radiation therapy in both primary and salvage treatment settings. |
Additional notable Decipher-focused presentations include:
|
Title: |
Decipher Risk Stratification of Radiorecurrent Prostate Cancer: Correlative Analysis of the F-SHARP Trial of Salvage Reirradiation |
|
|
Presenter: |
Abhishek Solanki, M.D., M.S., Loyola University Chicago |
|
|
Format: |
Poster (#L15) |
|
|
Abstract #: |
419 |
|
|
Date/Time: |
Thursday, February 13, 2025; 11:25 a.m.—12:45 p.m. PST |
|
|
Location: |
Level 1, West Hall; On Demand |
|
|
Summary: |
Radiation therapy is increasingly used for patients whose prostate cancer has recurred following initial radiation treatment. This study suggests the Decipher Prostate test can identify patients who are likely to benefit from more radiation alone versus those who may also need further treatment intensification. |
|
Title: |
Androgen receptor activity in biopsy specimens at initial diagnosis of prostate cancer and correlation with outcomes and treatment response |
|
|
Presenter: |
Nicole Handa, M.D., Northwestern University, Feinberg School of Medicine |
|
|
Format: |
Poster (#L5) |
|
|
Abstract #: |
409 |
|
|
Date/Time: |
Thursday, February 13, 2025; 11:25 a.m.—12:45 p.m. PST |
|
|
Location: |
Level 1, West Hall; On Demand |
|
|
Summary: |
Using the Decipher GRID research tool to assess transcriptome-wide expression data and clinical factors, investigators found that low androgen receptor activity (AR-A) was associated with poor outcomes for prostate cancer patients. They suggest such patients could potentially benefit from post-operative radiation therapy and PARP inhibitors. |
|
Title: |
Risk Stratification Using the Decipher 22-gene Genomic Classifier (GC) and Digital Pathology Artificial Intelligence (DPAI) in Nearly 10,000 Localized Prostate Cancer Patients |
|
|
Presenter: |
Daniel Spratt, M.D., University Hospitals Seidman Cancer Center, Case Western Reserve University |
|
|
Format: |
Poster (#L4) |
|
|
Abstract #: |
408 |
|
|
Date/Time: |
Thursday, February 13, 2025; 11:25 a.m.—12:45 p.m. PST |
|
|
Location: |
Level 1, West Hall; On Demand |
|
|
Summary: |
This large study found that adding digital pathology artificial intelligence (DPAI) tools to the Decipher Prostate Genomic Classifier did not further improve the molecular test’s prognostic performance. Ongoing research is underway to explore whether there may be specific clinical states where the combination of DPAI and the Decipher test may add meaningful clinical utility. |
“The extensive Decipher-focused data at the 2025 ASCO GU Symposium demonstrate the power of our novel Veracyte Diagnostics Platform, which begins with delivering high-performing tests using a comprehensive, whole-transcriptome approach. This enables additional research, which in turn supports further innovation to help more patients,” said Phillip Febbo, M.D., Veracyte’s chief scientific officer and chief medical officer.